Advancing Inflammatory Bowel Disease Treatment by Targeting the Innate Immune System and Precision Drug Delivery

Area of Science:

• Gastroenterology
• Immunology
• Nanomedicine

Background:

• Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is characterized by chronic gastrointestinal inflammation.
• Current therapies are ineffective for a significant patient subset and often cause adverse effects, necessitating novel treatment approaches.
• Neutrophils contribute to IBD pathogenesis through reactive oxygen species (ROS) and neutrophil extracellular traps (NETs), which damage the gut mucosa.

Purpose of the Study:

• To explore novel therapeutic strategies for IBD by targeting innate immune mechanisms and improving drug delivery.
• To investigate the potential of inhibiting neutrophil extracellular traps (NETs) as a therapeutic target in IBD.
• To evaluate advanced oral drug delivery systems designed for targeted delivery to inflamed regions of the gastrointestinal tract.

Main Methods:

• Review of recent studies on the role of neutrophils, ROS, DNA repair, and NET formation in IBD.
• Analysis of innovative oral drug delivery systems utilizing particle size, surface modifications, and ROS-triggered release for targeted gut delivery.
• Exploration of dual therapeutic strategies combining targeted drug delivery with novel molecular targets.

Main Results:

• Preclinical models demonstrate positive outcomes from NET inhibition, identifying NETs as a viable therapeutic target.
• Advanced drug delivery systems show potential for precise targeting of inflamed ileum and colon, minimizing systemic absorption and side effects.
• A synergistic approach combining NET inhibition with ROS-responsive nanocarriers may enhance treatment efficacy.

Conclusions:

• Targeting the innate immune system, particularly NET formation, offers a promising avenue for IBD treatment.
• Advanced, targeted oral drug delivery systems can improve therapeutic precision and reduce side effects in IBD management.
• A combined strategy of novel therapeutic targets and advanced drug delivery holds significant potential for improving patient outcomes in IBD.